Shingrix is a non-live, recombinant adjuvanted vaccine developed by GSK used to prevent herpes zoster (shingles) and its most common complication, postherpetic neuralgia (PHN). It is specifically designed to overcome the natural age-related decline in immunity against the varicella-zoster virus (VZV).